This drug entry is a stub and has not been fully annotated. It is scheduled to be annotated soon.
Identification
- Generic Name
- Fabomotizole
- DrugBank Accession Number
- DB13623
- Background
Not Available
- Type
- Small Molecule
- Groups
- Experimental
- Structure
Structure for Fabomotizole (DB13623)
- Weight
- Average: 307.41
Monoisotopic: 307.135448102 - Chemical Formula
- C15H21N3O2S
- Synonyms
- Fabomotizole
- External IDs
- CM-346
Pharmacology
- Indication
Not Available
Reduce drug development failure ratesBuild, train, & validate machine-learning modelswith evidence-based and structured datasets.Build, train, & validate predictive machine-learning models with structured datasets.- Contraindications & Blackbox Warnings
Prevent Adverse Drug Events TodayTap into our Clinical API for life-saving information on contraindications & blackbox warnings, population restrictions, harmful risks, & more.Avoid life-threatening adverse drug events with our Clinical API- Pharmacodynamics
Not Available
- Mechanism of action
- Not Available
- Absorption
Not Available
- Volume of distribution
Not Available
- Protein binding
Not Available
- Metabolism
- Not Available
- Route of elimination
Not Available
- Half-life
Not Available
- Clearance
Not Available
- Adverse Effects
Improve decision support & research outcomesWith structured adverse effects data, including: blackbox warnings, adverse reactions, warning & precautions, & incidence rates. View sample adverse effects data in our new Data Library!Improve decision support & research outcomes with our structured adverse effects data.- Toxicity
Not Available
- Pathways
- Not Available
- Pharmacogenomic Effects/ADRs
- Not Available
Interactions
- Drug Interactions
- This information should not be interpreted without the help of a healthcare provider. If you believe you are experiencing an interaction, contact a healthcare provider immediately. The absence of an interaction does not necessarily mean no interactions exist.
Drug Interaction Integrate drug-drug
interactions in your software1,2-Benzodiazepine The risk or severity of CNS depression can be increased when 1,2-Benzodiazepine is combined with Fabomotizole. Acetazolamide The risk or severity of CNS depression can be increased when Acetazolamide is combined with Fabomotizole. Acetophenazine The risk or severity of CNS depression can be increased when Acetophenazine is combined with Fabomotizole. Agomelatine The risk or severity of CNS depression can be increased when Agomelatine is combined with Fabomotizole. Alfentanil The risk or severity of CNS depression can be increased when Alfentanil is combined with Fabomotizole. Alimemazine The risk or severity of CNS depression can be increased when Alimemazine is combined with Fabomotizole. Almotriptan The risk or severity of CNS depression can be increased when Almotriptan is combined with Fabomotizole. Alosetron The risk or severity of CNS depression can be increased when Alosetron is combined with Fabomotizole. Alprazolam The risk or severity of CNS depression can be increased when Alprazolam is combined with Fabomotizole. Alverine The risk or severity of CNS depression can be increased when Alverine is combined with Fabomotizole. 
Identify potential medication risksEasily compare up to 40 drugs with our drug interaction checker.Get severity rating, description, and management advice.Learn more - Food Interactions
- Not Available
Categories
- ATC Codes
- N05BX04 — Fabomotizole
- Drug Categories
- Chemical TaxonomyProvided by Classyfire
- Description
- This compound belongs to the class of organic compounds known as benzimidazoles. These are organic compounds containing a benzene ring fused to an imidazole ring (five member ring containing a nitrogen atom, 4 carbon atoms, and two double bonds).
- Kingdom
- Organic compounds
- Super Class
- Organoheterocyclic compounds
- Class
- Benzimidazoles
- Sub Class
- Not Available
- Direct Parent
- Benzimidazoles
- Alternative Parents
- Phenol ethers / Alkylarylthioethers / Alkyl aryl ethers / Morpholines / Imidazoles / Heteroaromatic compounds / Trialkylamines / Sulfenyl compounds / Oxacyclic compounds / Dialkyl ethers show 2 more
- Substituents
- Alkyl aryl ether / Alkylarylthioether / Amine / Aromatic heteropolycyclic compound / Aryl thioether / Azacycle / Azole / Benzenoid / Benzimidazole / Dialkyl ether show 17 more
- Molecular Framework
- Aromatic heteropolycyclic compounds
- External Descriptors
- Not Available
- Affected organisms
- Not Available
Chemical Identifiers
- UNII
- 0F8K1X115C
- CAS number
- 173352-21-1
- InChI Key
- WWNUCVSRRUDYPP-UHFFFAOYSA-N
- InChI
- InChI=1S/C15H21N3O2S/c1-2-20-12-3-4-13-14(11-12)17-15(16-13)21-10-7-18-5-8-19-9-6-18/h3-4,11H,2,5-10H2,1H3,(H,16,17)
- IUPAC Name
- 5-ethoxy-2-{[2-(morpholin-4-yl)ethyl]sulfanyl}-1H-1,3-benzodiazole
- SMILES
- CCOC1=CC=C2NC(SCCN3CCOCC3)=NC2=C1
References
- General References
- Not Available
- External Links
- ChemSpider
- 8038633
- ChEBI
- 135309
- ChEMBL
- CHEMBL3707307
- ZINC
- ZINC000023139484
- Wikipedia
- Fabomotizole
Clinical Trials
- Clinical Trials
Phase Status Purpose Conditions Count 3 Not Yet Recruiting Treatment Generalized Anxiety Disorder 1
Pharmacoeconomics
- Manufacturers
- Not Available
- Packagers
- Not Available
- Dosage Forms
- Not Available
- Prices
- Not Available
- Patents
- Not Available
Properties
- State
- Not Available
- Experimental Properties
- Not Available
- Predicted Properties
Property Value Source Water Solubility 0.178 mg/mL ALOGPS logP 2.28 ALOGPS logP 2.31 Chemaxon logS -3.2 ALOGPS pKa (Strongest Acidic) 10.79 Chemaxon pKa (Strongest Basic) 6.67 Chemaxon Physiological Charge 0 Chemaxon Hydrogen Acceptor Count 4 Chemaxon Hydrogen Donor Count 1 Chemaxon Polar Surface Area 50.38 Å2 Chemaxon Rotatable Bond Count 6 Chemaxon Refractivity 85.71 m3·mol-1 Chemaxon Polarizability 34.94 Å3 Chemaxon Number of Rings 3 Chemaxon Bioavailability 1 Chemaxon Rule of Five Yes Chemaxon Ghose Filter Yes Chemaxon Veber's Rule No Chemaxon MDDR-like Rule Yes Chemaxon - Predicted ADMET Features
- Not Available
Spectra
- Mass Spec (NIST)
- Not Available
- Spectra
Spectrum Spectrum Type Splash Key Predicted MS/MS Spectrum - 10V, Positive (Annotated) Predicted LC-MS/MS Not Available Predicted MS/MS Spectrum - 20V, Positive (Annotated) Predicted LC-MS/MS Not Available Predicted MS/MS Spectrum - 40V, Positive (Annotated) Predicted LC-MS/MS Not Available Predicted MS/MS Spectrum - 10V, Negative (Annotated) Predicted LC-MS/MS Not Available Predicted MS/MS Spectrum - 20V, Negative (Annotated) Predicted LC-MS/MS Not Available Predicted MS/MS Spectrum - 40V, Negative (Annotated) Predicted LC-MS/MS Not Available
Drug created at June 23, 2017 20:45 / Updated at February 21, 2021 18:54